Clinical Trial Update: Intracystic Injection of NanoPac® in Subjects With Mucinous Cystic Pancreatic Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 trial assessing intracystic injection of NanoPac® in subjects with pancreatic mucinous-cystic neoplasms has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Mucinous Cystic Neoplasm

Drugs mentioned

• NanoPac (paclitaxel nanoparticle formulation)

Snippet

Sponsor: NanOlogy, LLC | Conditions: Pancreatic Mucinous-Cystic Neoplasm | Phase 2 | Status: COMPLETED | Results posted: 2021-06-08